Back to Search
Start Over
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.
- Source :
- Acta Oncologica; Jan2020, Vol. 59 Issue 1, p75-81, 7p, 1 Diagram, 3 Charts
- Publication Year :
- 2020
-
Abstract
- Introduction: Myelosuppresion is a common side effect of chemotherapy and granulocyte-colony stimulating factor (G-CSF) is often used to reduce the risk of neutropenic events. The purpose of this exploratory analysis was to investigate neutropenic complications in the phase III PANTHER trial of standard 3-weekly chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide plus docetaxel (FEC/D) versus bi-weekly tailored dose-dense EC/D adjuvant chemotherapy in breast cancer. Patients and methods: Febrile neutropenia, neutropenic infection and infection grade 3–4 according to CTC AE 3.0, were explored in relation to G-CSF use. Per cycle analysis was performed concerning dose reduction and dose delays in conjunction with G-CSF administration. Results: In the experimental group, 98.9% of patients received primary G-CSF support during EC and 97.4% during docetaxel, compared with 49.7% during FEC and 63.88% during docetaxel in the standard group. Overall, the use of G-CSF was associated with a lower risk for developing neutropenic events (OR 0.44, 95% CI 0.35–0.55, p <.001). Chemotherapy delays due to neutropenia and leukopenia were significantly decreased among patients that received G-CSF (OR 0.098, 95% CI 0.06–0.15 and OR 0.32, 95% CI 0.18–0.58, respectively). Discussion: In conclusion, G-CSF support reduces neutropenic events and permits increased relative dose intensity, which is essential for improved survival outcomes. [ABSTRACT FROM AUTHOR]
- Subjects :
- BREAST tumors
COMBINED modality therapy
CONFIDENCE intervals
DOSE-effect relationship in pharmacology
FEBRILE neutropenia
GRANULOCYTE-colony stimulating factor
FLUOROURACIL
LEUCOPENIA
RESEARCH
SURVIVAL
TUMOR classification
DOCETAXEL
RANDOMIZED controlled trials
CYCLOPHOSPHAMIDE
EPIRUBICIN
ODDS ratio
DISEASE risk factors
Subjects
Details
- Language :
- English
- ISSN :
- 0284186X
- Volume :
- 59
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Acta Oncologica
- Publication Type :
- Academic Journal
- Accession number :
- 140466982
- Full Text :
- https://doi.org/10.1080/0284186X.2019.1670353